Abstract:In December 2021, the U.S. Food and Drug Administration (FDA) issued emergency use authorizations (EUAs) for two oral antiviral at-home treatments for coronavirus disease 2019 (COVID-19), nirmatrelvir/ritonavir (Paxlovid [Pfizer]), and molnupiravir (Merck).[1] While their mechanisms of action somewhat differ, these agents are considered "game-changers" by some observers, since they do not require administration by intravenous infusion as monoclonal antibodies do. Initial efficacy studies suggest that nirmatrelvir/ritonavir may be more effective than molnupiravir,[1] but it also has more drug interactions of potential concern, especially related to anticoagulant therapy.[1] Molnupiravir does not have any reported interaction with anticoagulant agents.[2] Additionally, remdesivir (Veklury [Gilead]) and bebtelovimab (Lilly) are parenteral agents recently granted an EUA for use in the outpatient setting as treatment of mild-to-moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, who are at high risk for progression to severe COVID-19, including hospitalization or death.[3] Neither of these agents have any known interaction with anticoagulants.[2] Nirmatrelvir/ritonavir is comprised of nirmatrelvir, a SARS-CoV-2 main protease inhibitor, co-packaged with ritonavir, a protease inhibitor.[4] While ritonavir has no activity against SARS-CoV-2, its inhibition of CYP3A-mediated metabolism of nirmatrelvir increases nirmatrelvir plasma concentrations to levels anticipated to inhibit SARS-CoV-2 replication. Outpatient nirmatrelvir/ritonavir use is authorized for treatment of mild to moderate COVID-19 disease in adults and pediatric patients older than 12 and weighting more than 40 kg who are at high risk for severe progression of COVID-19. Regarding pharmacokinetics, nirmatrelvir is primarily eliminated by the kidneys, with minimal liver metabolism.[4] However, ritonavir is known to be an inhibitor of cytochrome P450 (CYP) isoenzymes, particularly a strong CYP3A4 and weak 2D6 inhibitor, and an inhibitor of P-glycoprotein (P-gp).[5] [6] Additionally, ritonavir is an inducer of CYP 1A2, 2B6, 2C19, and 2C9.[5] On that premise, the risk of drug interactions with nirmatrelvir/ritonavir and many commonly used medications, including statins and antiarrhythmic drugs, may preclude its use or need careful adjustment of dosing. Additionally, the FDA label flags two anticoagulants for nirmatrelvir/ritonavir users, rivaroxaban and warfarin, while other direct oral anticoagulants (DOACs) are not mentioned. Inhibition of CYP3A4 and P-gp leads to increased plasma levels and pharmacodynamic effects of rivaroxaban, thus potentially increasing bleeding risk (area under the curve [AUC] change 153%, maximum concentration ( C max ) change 53%).[7] Antiplatelet or anticoagulant therapy is not currently recommended for outpatients with COVID-19, the largest population of individuals infected.[3] [8] [9] The ACTIV-4B Outpatient Thrombosis Prevention Trial,[10] aimed at evaluating antithrombotic therapy in outpatients with COVID-19, was a randomized, adaptive, double-blind, placebo-controlled trial that randomly assigned outpatients with COVID-19 in a 1:1:1:1 ratio to receive aspirin (81 mg orally once daily), prophylactic-dose apixaban (2.5 mg orally twice daily), therapeutic-dose apixaban (5 mg orally twice daily), or matching placebo for 45 days. Treatment with aspirin or apixaban compared with placebo did not reduce the rate of composite clinical outcomes, with risk of adjudicated primary composite outcome with placebo being 0.0% (95% CI, 0.0–2.8%), with aspirin 0.0% (95% CI, 0.0–2.6%), 0.7% in the prophylactic apixaban group (95% CI, 0.1–4.1%) and 1.4% in therapeutic apixaban group (95% CI, 0.4% −5.0%), respectively. In addition, a phase 2b placebo controlled randomized study of rivaroxaban 10 mg daily in patients with COVID-19 not currently hospitalized or under immediate consideration for hospitalization was terminated, after almost 500 of the target 600 participants were enrolled because a prespecified interim analysis of the first 200 participants in the intent-to-treat population demonstrated it would be futile to attempt to show a beneficial effect of rivaroxaban in this patient population. Disease progression rate with rivaroxaban was 20.7 versus 19.8% in placebo groups, with non-significant risk difference of –1.0 (95% confidence interval, −6.4 to 8.4%; p = 0.78).[11] Thus, at this time, routine anticoagulation is not recommended for patients with COVID-19 who do not need hospitalization. Despite these findings, patients at high risk of thrombosis are usually prescribed long-term anticoagulation therapy. Moreover, COVID-19 patients who require anticoagulants for atrial fibrillation or flutter, recent surgery or immobility, heart valve replacement, ischemic stro -Abstract Truncated-

Molnupiravir and Nirmatrelvir-Ritonavir: Oral COVID Antiviral Drugs

A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir

Nirmatrelvir or Molnupiravir Use and Severe Outcomes from Omicron Infections.

Advances and Challenges in Using Nirmatrelvir and Its Derivatives Against SARS-CoV-2 Infection.

Proposal for a Simple Algorithmic Approach to Manage Drug–Drug Interactions of Oral Anticoagulants with Nirmatrelvir/Ritonavir in COVID-19 Outpatients

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?

New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19

A Systematic Review of Nirmatrelvir/Ritonavir and Molnupiravir for the Treatment of Coronavirus Disease 2019

Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19

Molnupiravir, an Oral Antiviral Treatment for COVID-19

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study

The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations

Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19

Nirmatrelvir Plus Ritonavir: First Approval

Comparison of safety and efficacy between Nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney disease: a retrospective observational study

Efficacy and Safety of Nirmatrelvir/Ritonavir in Severe Hospitalized Patients with COVID-19 and in Patients at High Risk for Progression to Critical Illness: A Real-World Study

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study

Nirmatrelvir/ritonavir for Patients with SARS-CoV-2 Infection and Impaired Kidney Function During the Omicron Surge

Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models

Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19–Related Hospitalization and Mortality: A Systematic Literature Review